This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agios (AGIO) Progressing Well on Pipeline Amid Competition
by Zacks Equity Research
Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss
by Zacks Equity Research
Agios posted wider-than-expected loss in the first quarter of 2018. Revenues came below expectations. Revenues also decreased year-over-year.
Why Earnings Season Could Be Great for Agios (AGIO)
by Zacks Equity Research
Agios (AGIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
by Zacks Equity Research
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Pharma M&A Active This Week: 4 Potential Buyout Targets
by Indrajit Bandyopadhyay
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Agios Pharmaceuticals Shares Rise on Buyout Speculation
by Zacks Equity Research
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss
by Zacks Equity Research
Agios (AGIO) posted wider-than-expected loss in the fourth quarter of 2017. Revenues came below expectations. Revenues also decreased year-over-year.
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.
Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?
by Zacks Equity Research
Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.
What's in the Cards for Varian Medical (VAR) in Q1 Earnings?
by Zacks Equity Research
Varian Medical's (VAR) lackluster performance in Halcyon platform and disappointing financials are likely to dampen results in Q1.
Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year
by Zacks Equity Research
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.
Celgene Provides 2017 Preliminary Results & 2018 View
by Zacks Equity Research
Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.
Celgene to Acquire Impact Biomedicines to Boost Pipeline
by Zacks Equity Research
Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.
Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?
by Zacks Equity Research
Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.
Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.
by Zacks Equity Research
Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.
Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
by Arpita Dutt
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
Celgene (CELG) Down on Discouraging Data on Revlimid
by Zacks Equity Research
Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.
Agios Posts New Data on Glioma Candidate from Dose Expansion
by Zacks Equity Research
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.
Agios (AGIO) Q3 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Agios posted narrower-than-expected loss in the third quarter of 2017. Revenues came above expectations. Revenues also increased year-over-year.